v3.26.1
REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS (Details) - USD ($)
Jun. 30, 2026
Mar. 31, 2026
Dec. 31, 2025
Jun. 30, 2025
Mar. 31, 2025
Dec. 31, 2024
Current assets:            
Cash $ 21,237   $ 139,360 $ 111,872   $ 88,033
Accounts receivable, net 67,694   253,459      
Grant receivable 102,613   52,026      
Inventory 43,551   143,425      
Prepaid expenses 388,282   226,198      
Total current assets 623,377   814,468      
Property and equipment, net 0   4,062      
Right to use assets 137,869   159,128      
Other assets:            
Intangible assets, net 541,119   564,460      
Goodwill 563,158   563,158      
Deposits, long term 41,936   41,936      
Total other assets 1,146,213   1,169,554      
Total assets 1,907,459   2,147,212      
Current liabilities:            
Accounts payable and accrued expenses 6,763,370   6,362,728      
Lease liability, short term 45,146   43,382      
Notes payable, net of debt discounts 1,271,884   1,222,730      
Total current liabilities 8,854,703   8,306,199      
Long term liabilities:            
Royalty liability 348,155   359,378      
Lease liability, long term 92,723   115,745      
Total liabilities 14,379,077   13,674,200      
Deficit:            
Common stock, $0.001 par value; 750,000,000 shares authorized, 28,906,559 shares issued and outstanding as of March 31, 2026 29,666   24,489      
Common stock subscribed 100,000   100,000      
Additional paid in capital 76,183,780   75,279,624      
Accumulated deficit (88,559,898)   (86,649,288)      
Total deficit attributable to BioCorRx, Inc. (12,224,836)   (11,223,559)      
Non-controlling interest (246,782)   (303,429) (389,027)   (234,812)
Total deficit (12,471,618) $ (11,774,469) (11,526,988) $ (13,013,229) $ (11,801,575) $ (12,355,232)
Total liabilities and deficit 1,907,459   2,147,212      
Total liabilities and deficit (1,907,459)   (2,147,212)      
As Revised [Member]            
Current assets:            
Cash   211,911 139,360      
Accounts receivable, net   179,148        
Grant receivable   121,720        
Inventory   143,425        
Prepaid expenses   212,810        
Total current assets   869,014        
Property and equipment, net   1,452        
Right to use assets   148,604        
Other assets:            
Intangible assets, net   549,501        
Goodwill   563,158        
Deposits, long term   41,936        
Total other assets   1,154,595        
Total assets   2,173,665        
Current liabilities:            
Accounts payable and accrued expenses   6,585,014        
Lease liability, short term   44,255        
Notes payable, net of debt discounts   1,239,434        
Notes payable, related parties, net of debt discount   658,263        
Total current liabilities   8,526,966        
Long term liabilities:            
Economic Injury Disaster loan, long term   69,155        
Royalty liability   351,492        
Royalty obligation, net of discount   4,896,172        
Lease liability, long term   104,349        
Total liabilities   13,948,134        
Deficit:            
Common stock, $0.001 par value; 750,000,000 shares authorized, 28,906,559 shares issued and outstanding as of March 31, 2026   28,906        
Common stock subscribed   100,000        
Additional paid in capital   75,879,983        
Accumulated deficit   (87,595,124)        
Total deficit attributable to BioCorRx, Inc.   (11,564,619)        
Non-controlling interest   (209,850)        
Total deficit   (11,774,469) (11,526,988)      
Total liabilities and deficit   2,173,665        
Total liabilities and deficit   (2,173,665)        
Revision [Member]            
Current assets:            
Cash   0 0      
Accounts receivable, net   151,200        
Grant receivable   0        
Inventory   0        
Prepaid expenses   0        
Total current assets   151,200        
Property and equipment, net   0        
Right to use assets   0        
Other assets:            
Intangible assets, net   0        
Goodwill   0        
Deposits, long term   0        
Total other assets   0        
Total assets   151,200        
Current liabilities:            
Accounts payable and accrued expenses   0        
Lease liability, short term   0        
Notes payable, net of debt discounts   0        
Notes payable, related parties, net of debt discount   0        
Total current liabilities   0        
Long term liabilities:            
Economic Injury Disaster loan, long term   0        
Royalty liability   0        
Royalty obligation, net of discount   0        
Lease liability, long term   0        
Total liabilities   0        
Deficit:            
Common stock, $0.001 par value; 750,000,000 shares authorized, 28,906,559 shares issued and outstanding as of March 31, 2026   0        
Common stock subscribed   0        
Additional paid in capital   0        
Accumulated deficit   (114,609)        
Total deficit attributable to BioCorRx, Inc.   (114,609)        
Non-controlling interest   (36,591)        
Total deficit   (151,200) 0      
Total liabilities and deficit   151,200        
Total liabilities and deficit   (151,200)        
As Reported [Member]            
Current assets:            
Cash   211,911 139,360      
Accounts receivable, net   330,348        
Grant receivable   121,720        
Inventory   143,425        
Prepaid expenses   212,810        
Total current assets   1,020,214        
Property and equipment, net   1,452        
Right to use assets   148,604        
Other assets:            
Intangible assets, net   549,501        
Goodwill   563,158        
Deposits, long term   41,936        
Total other assets   1,154,595        
Total assets   2,324,865        
Current liabilities:            
Accounts payable and accrued expenses   6,585,014        
Lease liability, short term   44,255        
Notes payable, net of debt discounts   1,239,434        
Notes payable, related parties, net of debt discount   658,263        
Total current liabilities   8,526,966        
Long term liabilities:            
Economic Injury Disaster loan, long term   69,155        
Royalty liability   351,492        
Royalty obligation, net of discount   4,896,172        
Lease liability, long term   104,349        
Total liabilities   13,948,134        
Deficit:            
Common stock, $0.001 par value; 750,000,000 shares authorized, 28,906,559 shares issued and outstanding as of March 31, 2026   28,906        
Common stock subscribed   100,000        
Additional paid in capital   75,879,983        
Accumulated deficit   (87,480,515)        
Total deficit attributable to BioCorRx, Inc.   (11,450,010)        
Non-controlling interest   (173,259)        
Total deficit   (11,623,269)        
Total liabilities and deficit   2,324,865        
Total liabilities and deficit   (2,324,865)        
Series A Convertible Preferred Stock [Member]            
Deficit:            
Preferred Stock Value 16,000   16,000      
Series A Convertible Preferred Stock [Member] | As Revised [Member]            
Deficit:            
Preferred Stock Value   16,000        
Series A Convertible Preferred Stock [Member] | Revision [Member]            
Deficit:            
Preferred Stock Value   0        
Series B Convertible Preferred Stock [Member]            
Deficit:            
Preferred Stock Value $ 5,616   5,616      
Series B Convertible Preferred Stock [Member] | As Revised [Member]            
Deficit:            
Preferred Stock Value   5,616        
Series B Convertible Preferred Stock [Member] | Revision [Member]            
Deficit:            
Total deficit   0 $ 0      
Preferred Stock Value   0        
Series B Convertible Preferred Stock [Member] | As Reported [Member]            
Deficit:            
Preferred Stock Value   5,616        
Convertible Series A Preferred Stock [Member] | As Reported [Member]            
Deficit:            
Preferred Stock Value   $ 16,000